相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Keelan Z. Guiley et al.
CANCER DISCOVERY (2023)
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
Huaxin Song et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Eytan M. Stein et al.
CLINICAL CANCER RESEARCH (2022)
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of Concept, Phase Ib Study
Albiruni R. Abdul Razak et al.
CLINICAL CANCER RESEARCH (2022)
Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
Shengliang Zhang et al.
MOLECULAR CANCER RESEARCH (2022)
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Yigang Tang et al.
CELL REPORTS (2022)
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
Meredith McKean et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2).
Ecaterina Elena Dumbrava et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS).
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Ecaterina Elena Dumbrava et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC).
Michael K.K. Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin
Mohamed Alalem et al.
CANCERS (2022)
DNAJA1-and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen
Shigeto Nishikawa et al.
CELL DEATH DISCOVERY (2022)
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Shuo Chen et al.
CANCER CELL (2021)
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
David A. Sallman et al.
BLOOD (2021)
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
Sebastian Bauer et al.
BRITISH JOURNAL OF CANCER (2021)
Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function
L. Palanikumar et al.
NATURE COMMUNICATIONS (2021)
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
Seyed Pairawan et al.
BREAST CANCER RESEARCH (2021)
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
Pau Montesinos et al.
FUTURE ONCOLOGY (2020)
Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks
Sara Lundsten et al.
NANOMATERIALS (2020)
Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
M.M. Gounder et al.
EUROPEAN JOURNAL OF CANCER (2020)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Parisa Malekzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms
Antje Lindemann et al.
CLINICAL CANCER RESEARCH (2019)
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
Luciana P. Rangel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles
Tsz Ying Yuen et al.
CHEMICAL SCIENCE (2019)
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis
Eleonora Ingallina et al.
NATURE CELL BIOLOGY (2018)
Reactivating TP53 signaling by the novel MDM2 inhibitor DS3032b as a therapeutic option for high-risk neuroblastoma
Viktor Arnhold et al.
ONCOTARGET (2018)
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors
Diana Spiegelberg et al.
CANCER RESEARCH (2018)
An Update on MDMX and Dual MDM2/X Inhibitors
Margarida Espadinha et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
Maciej Dabrowski et al.
MOLECULAR MEDICINE (2018)
Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines
Saman Maleki Vareki et al.
PLOS ONE (2018)
Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
Lena Haffo et al.
SCIENTIFIC REPORTS (2018)
The interplay between mutant p53 and the mevalonate pathway
Alejandro Parrales et al.
CELL DEATH AND DIFFERENTIATION (2018)
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
N. C. Synnott et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Andrew J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53
Xin Yu et al.
MOLECULAR PHARMACOLOGY (2017)
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model
Emilie A. Chapeau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Inhibiting the system x(C)over-bar/glutathione axis selectively targets cancers with mutant-p53 accumulation
David S. Liu et al.
NATURE COMMUNICATIONS (2017)
Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search
Si Chen et al.
RSC ADVANCES (2017)
Molecularly targeted therapies for p53-mutant cancers
Dekuang Zhao et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff et al.
CLINICAL CANCER RESEARCH (2016)
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Alice Soragni et al.
CANCER CELL (2016)
Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties
Surendra R. Punganuru et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Effect of Mutation on an Aggregation-Prone Segment of p53: From Monomer to Dimer to Multimer
Atanu Das et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2016)
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
Farhad Ravandi et al.
LEUKEMIA RESEARCH (2016)
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Alejandro Parrales et al.
NATURE CELL BIOLOGY (2016)
Initial Testing (Stage 1) of MK-8242A Novel MDM2 Inhibitorby the Pediatric Preclinical Testing Program
Min H. Kang et al.
PEDIATRIC BLOOD & CANCER (2016)
Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides
Siau Jia Wei et al.
ONCOTARGET (2016)
COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
Kowthar Y. Salim et al.
ONCOTARGET (2016)
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).
Charlie Gourley et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
TP53: an oncogene in disguise
T. Soussi et al.
CELL DEATH AND DIFFERENTIATION (2015)
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
Masatsugu Hiraki et al.
CHEMISTRY & BIOLOGY (2015)
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer
Adam R. Blanden et al.
DRUG DISCOVERY TODAY (2015)
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
David S. H. Liu et al.
GUT (2015)
Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Abdullah A. Osman et al.
MOLECULAR CANCER THERAPEUTICS (2015)
An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore
Adam R. Blanden et al.
MOLECULAR PHARMACOLOGY (2015)
Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in p53
Saikat Ghosh et al.
BIOCHEMISTRY (2014)
SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang et al.
CANCER RESEARCH (2014)
Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations
Leenus Martin et al.
CANCER RESEARCH (2014)
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Bernard Leroy et al.
HUMAN MUTATION (2014)
RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
A. Weilbacher et al.
CELL DEATH & DISEASE (2014)
Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism
Xin Yu et al.
ONCOTARGET (2014)
Stapled Peptides with Improved Potency and Specificity That Activate p53
Christopher J. Brown et al.
ACS CHEMICAL BIOLOGY (2013)
Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro
Mikhail Burmakin et al.
CLINICAL CANCER RESEARCH (2013)
Chaperone-mediated autophagy degrades mutant p53
Helin Vakifahmetoglu-Norberg et al.
GENES & DEVELOPMENT (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Small molecule induced reactivation of mutant p53 in cancer cells
Xiangrui Liu et al.
NUCLEIC ACIDS RESEARCH (2013)
Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET
Ruby Shalom-Feuerstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations
Jinfeng Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
X. Peng et al.
CELL DEATH & DISEASE (2013)
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Bradford Graves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cancer syndromes and therapy by stop-codon readthrough
Renata Bordeira-Carrico et al.
TRENDS IN MOLECULAR MEDICINE (2012)
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Javier E. Girardini et al.
CANCER CELL (2011)
PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
Roza Zandi et al.
CLINICAL CANCER RESEARCH (2011)
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Jie Xu et al.
NATURE CHEMICAL BIOLOGY (2011)
Rescue of p53 Function by Small-Molecule RITA in Cervical Carcinoma by Blocking E6-Mediated Degradation
Carolyn Ying Zhao et al.
CANCER RESEARCH (2010)
Mdm2-mediated ubiquitylation: p53 and beyond
J-C Marine et al.
CELL DEATH AND DIFFERENTIATION (2010)
The missing Zinc: p53 misfolding and cancer
Stewart N. Loh
METALLOMICS (2010)
PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
N. Rokaeus et al.
ONCOGENE (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Heat Shock Protein 40: Structural Studies and Their Functional Implications
Jingzhi Li et al.
PROTEIN AND PEPTIDE LETTERS (2009)
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2
Yi-Chu Lin et al.
CANCER RESEARCH (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
J. E. Kravchenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cancer-derived p53 mutants suppress p53-target gene expression - potential mechanism for gain of function of mutant p53
Faina Vikhanskaya et al.
NUCLEIC ACIDS RESEARCH (2007)
The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones
X-B. Qiu et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma
Tom Van Maerken et al.
CANCER RESEARCH (2006)
Modulating molecular chaperone Hsp90 functions through reversible acetylation
S Aoyagi et al.
TRENDS IN CELL BIOLOGY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
VJN Bykov et al.
ONCOGENE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
MDM2 promotes ubiquitination and degradation of MDMX
Y Pan et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms
R Stad et al.
EMBO REPORTS (2001)
The role of tetramerization in p53 function
P Chène
ONCOGENE (2001)
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
WG Lu et al.
ONCOGENE (2000)
分享论文
